BERLIN — Bayer has announced a leadership change within its Pharmaceuticals’ Worldwide Markets organization to accelerate the strong performance and growth of its key pharmaceutical products in the U.S.
Effective May 1, 2026, Nelson Ambrogio, currently President of Bayer’s global Radiology business, will be appointed president of Bayer U.S. Pharmaceuticals. Nelson Ambrogio will guide the U.S. Pharmaceuticals organization into its next chapter of growth and build on the strong momentum and performance of the company’s pharmaceutical business in its largest and fastest-growing market.
Nelson Ambrogio will be responsible for commercial pharmaceutical operations in the U.S. during a pivotal time of growth for the business, ensuring the continued strong performance of Bayer’s key growth brands in prostate cancer, cardiovascular care, women’s healthcare and as the company prepares its future portfolio in secondary stroke prevention. Nelson Ambrogio will join the company’s Worldwide Markets Leadership Team, reporting directly to Sebastian Guth, Chief Operating Officer of Bayer’s Pharmaceuticals Division.
Sebastian Guth will continue to oversee the growth of all global markets in his role as Chief Operating Officer of Bayer Pharmaceuticals as the company accelerates its momentum. He will retain his role as the President of the Bayer Group in the U.S. and remain based in New Jersey.
“Nelson Ambrogio is an exceptional business and people leader who delivered strong growth in our global Radiology business over the past two years,” said Sebastian Guth, Chief Operating Officer of the Bayer Pharmaceuticals division and member of the company’s Pharmaceuticals Leadership Team. “Nelson Ambrogio has a deep understanding of our U.S. pharmaceuticals business, having previously led the growth and success of our oncology and women’s healthcare businesses while serving on our U.S. Pharmaceuticals Leadership Team. I look forward to his strong leadership and counsel as we continue our path of accelerated growth in the U.S. and deliver for customers and patients.”
“I am honored to assume the role of President of Bayer U.S. Pharmaceuticals,” said Nelson Ambrogio. “Throughout my time at Bayer, I’ve been privileged to work alongside exceptional colleagues across the globe who are deeply committed to serving our customers and patients and supporting Bayer’s mission. I look forward to joining our U.S. pharmaceuticals team and building upon Bayer’s success.”
